Immuno-Oncology Clinical Trials Market Size to Surpass USD 18.1 Bn by 2030

 According to the global Immuno-Oncology Clinical Trials market size is expected to surpass around USD 18.1 billion by 2030 from valued at USD 6.3 billion in 2021 and growing at a CAGR of 14.6% from 2022 to 2030.

The growth can be attributed to recent developments in immuno-oncology, changes in lifestyle brought on by urbanization predisposing populations to the rise of cancer, and the growing acceptability of targeted therapy.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7294

COVID-19 has had a significant impact on cancer and clinical trials, altering therapy and oncology patients in a number of ways. According to the research by Evaluate Vantage, over 170 studies being discontinued as a result of the virus. The pandemic disrupted 920 interventional oncology trials between February and May 2020.

 Besides, clinical trial participation has also become challenging due to difficulties such as transportation issues to trial sites or testing locations. IQVIA and the Cancer Research Institute collaborated to conduct a survey among oncology investigators to assess the impact of COVID-19 on ongoing and future clinical studies. Remote tools were highly ranked for the assessments. Also, during the COVID-19 pandemic, several regional authorities provided prompt and detailed support for virtual tools and models, indicating that regulators regard patient-centric technology and approaches as feasible answers to this global issue.

Immuno-oncology trials account for more than a third of all clinical trials in oncology. Small biotech and specialty pharma are poised to play a critical role in the growth. Immunotherapy advances differ from cytotoxic chemotherapy in the way they work, and these distinctions may have an influence on a dose, response evaluation, biomarker validation, combination therapy selection, and adverse event detection. Understanding and overcoming these barriers will be crucial to the success of immuno-oncology clinical trials and, eventually, market approval.

Report Scope of the Immuno-oncology Clinical Trials Market

Key Takeaways:

• Phase III dominated the market with the largest share of 54.2% in 2021. In 2019, 30.0% of Phase III drugs have a higher-than-average chance of approval, up from 25.2% in 2018
• The interventional experiments accounted for more than 79.6% of the market share in 2020
• The segment of solid tumors held 57.0% of the revenue share in 2021. This is largely attributed to the rise in the prevalence of solid tumors
• North America dominated the market and accounted for the largest revenue share of 52.0% in 2021. This is due to the rising adoption of personalized medicine-focused novel treatment methods, as well as the government funding and investments
• Asia Pacific is expected to register the fastest growth rate of 15.7% over the forecast period. At the end of 2021, over 42.0% of current immuno-oncology clinical experiments involved at least one location in the region

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7294

Regional Insights

North America dominated the market and accounted for the largest revenue share of 52.0% in 2021. This growth is attributed to the growing demand for personalized medicine-based novel treatments. In addition, increasing financial support from the government is also propelling the growth of the market in the region.  

Asia Pacific is anticipated to register the fastest growth rate of 15.7% throughout the forecast period. An increasing number of biotechnology companies are going to Asia and Australia to conduct immune-oncology clinical studies. Melanoma, lung cancer, bladder cancer, stomach cancer, and esophageal cancer are known to be more responsive to immune-oncology trials. Over 600 locations throughout the Asia Pacific have been involved in the clinical development of IO drugs, and hundreds more have gained valuable knowledge and skill managing clinical trials with immunotherapies, both monotherapy and combination medicines. These trials are mostly held in countries like China, Australia, and South Korea.

India is on pace to become a significant hub for immuno-oncology clinical trials and should be routinely considered by foreign sponsors for the use of immuno-oncology (IO) medicines such as immune checkpoint inhibitors in clinical care and solid tumor clinical trials. The most prevalent types of cancer recorded in India include breast, oral, cervical, lung, stomach, and colorectal cancers. Various government-funded and private cancer hospitals and research institutes with cutting-edge infrastructure that can handle multi-center immune-oncology clinical trials can be located throughout the country. These factors make the country highly cost-effective. With precise standards, the Indian regulatory authority is speeding up the discovery of new drugs and making immune-oncology clinical trials more accessible.

Some of the prominent players in the Immuno-oncology Clinical Trials Market include:

• Medpace
• Novartis
• Exscientia
• Syneous Health
• AstraZeneca

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Immuno-oncology Clinical Trials market

• Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

• Design
  • Interventional trials
  • Observational trials
  • Expanded access trials

• Indication
  • Solid tumors
  • Hematological cancer

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Immuno-Oncology Clinical Trials industry analysis from 2022 to 2030 to identify the prevailing Immuno-Oncology Clinical Trials industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Immuno-Oncology Clinical Trials industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Immuno-Oncology Clinical Trials industry trends, key players, market segments, application areas, and market growth strategies.

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7294

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/